News

Glioblastoma slowdown
Enlarge image

Clinical TrialsSwitzerland

Glioblastoma slowdown

13.08.2012 - Phase III results of Roche's unit Genentech Inc. show that a combination therapy including Avastin can significantly extend progression-free survival of patients with glioblastoma.

The AVAglio study investigating Avastin (bevacizumab) plus radiation and temozolomide chemotherapy (Merck's Temodar) in newly diagnosed brain tumour patients has met its co-primary endpoint of a significant improvement in progression-free survival compared with radiation and temozolomide chemotherapy alone. No new safety findings were observed in, and adverse events were consistent with those seen in previous trials of Avastin across its approved tumour types.

Data for the co-primary endpoint of overall survival are expected in 2013. The double-blind, international trial enrolled 921 patients. Basel-headquartered Roche and Genentech plan to discuss the results with EMA, FDA and other global regulatory authorities.

Avastin is currently approved in the US for adults with glioblastoma who have progressive disease following prior therapy and is only licensed for use as a single therapy and not in combination with other treatments. The product is not approved for glioblastoma in Europe.

FinancingSwitzerlandUKSwedenGermany

25.04.2014 Crispr Therapeutics has raised $25m in a series A investment. With the money, the newly formed Swiss biopharma company plans on translating its gene editing technology into medicines for genetic diseases.

BusinessSwitzerlandUK

23.04.2014 In an effort to focus on key businesses, pharma giant Novartis is joining forces with long-time rival GlaxoSmithKline in a multi-billion Euro asset exchange and an OTC joint venture.

FinanceSwedenFrance

18.04.2014 Oxthera AB, a Swedish biopharma company with a focus on rare diseases, has gained a SEK70m cash injection to continue its clinical programme for primary hyperoxaluria.

FundingEU

17.04.2014 The European Parliament has given green light to the second Innovative Medicines Initiative with the aim to advance pharmacological research and development, particularly in areas of unmet medical need.

BusinessGermanyFrance

15.04.2014 German flavour and scent specialist Symrise has announced its plans to acquire French pet-food ingredients maker Diana Group for €1.3bn.

BioeconomySpain

14.04.2014 Spanish Neol Biosolutions and the Center for Second Generation Biofuels are starting a partnership to scale-up Neol's waste-to-oil technology.

EvidenceUKSwitzerland

11.04.2014 There is no evidence that neuraminidase inhibitors Tamiflu and Relenza prevent complications of influenza or reduce hospital admissions. In addition, it is unclear whether they can stop the spread of influenza in case of outbreaks, says a report by the Cochrane Collaboration.

BusinessSwitzerlandSpain

09.04.2014 Roche is extending its involvement in the area of point-of-care diagnostics by taking over US company Iquum. In the field of epigenetics, the Swiss pharma company has started a cooperation with the Spanish company Oryzon.

Status ReportSwitzerland

08.04.2014 The Swiss Biotech Report 2014 presented in Zurich sees an encouraging upturn in the country's biotech scene. However, the acceptance of the mass immigration initiative poses a significant threat.

NanobiotechnologyItaly

07.04.2014 Scientists from the University of Udine have designed, produced and tested a prototype for a "DNA origami" nanorobot that can potentially deliver biological activators in-vivo.

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • RENEURON (UK)3.60 GBP13.6%
  • EPIGENOMICS (D)5.74 EUR10.4%
  • PROTHENA PLC (IE)36.95 USD9.5%

FLOP

  • CYTOS (CH)0.13 CHF-18.8%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • THERAMETRICS (CH)0.10 CHF-9.1%

TOP

  • BIOTECH PHARMACON (N)19.00 NOK67.4%
  • WILEX (D)0.82 EUR39.0%
  • E-THERAPEUTICS (UK)28.00 GBP34.9%

FLOP

  • CYTOS (CH)0.13 CHF-95.2%
  • BIONOR PHARMA (N)2.18 NOK-45.5%
  • DIAGENIC (N)0.78 NOK-38.1%

TOP

  • SILENCE THERAPEUTICS (UK)255.00 GBP6275.0%
  • IXICO (UK)67.00 GBP740.7%
  • PLETHORA (UK)10.62 GBP658.6%

FLOP

  • CYTOS (CH)0.13 CHF-96.8%
  • EVOCUTIS (UK)0.22 GBP-91.9%
  • ADDEX (CH)1.95 CHF-71.1%

No liability assumed, Date: 24.04.2014